Auto-populated list of related Clinical Trials
(Breast, Cleft Lip and Palate, Hand, Lymphedema, Oral, Skin, Trauma)

Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers

This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444 as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Corvus Pharmaceuticals, Inc.

Collaborator: Genentech, Inc.

Intervention(s):

  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444 + atezolizumab
  • Drug: CPI-444

Phase:

Phase 1

Eligibility


Inclusion Criteria

   1. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

   2. Documented incurable cancer with one of the following histologies: non-small cell lung
   cancer, malignant melanoma, renal cell cancer, triple negative breast cancer,
   colorectal cancer with microsatellite instability (MSI), bladder cancer, and
   metastatic castration resistant prostate cancer.

   3. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST
   1.1).

   4. At least 1 but not more than 5 prior systemic therapies for advanced/recurrent or
   progressing disease.

Exclusion Criteria

   1. History of severe hypersensitivity reaction to monoclonal antibodies.

   2. Any active autoimmune disease or a documented history of serious autoimmune disease
   within the past 5 years requiring immunosuppressive therapy.

   3. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
   pneumonitis, idiopathic pneumonitis, or clinical symptoms of active pneumonitis.

   4. The use of any investigational medication or device in the 30 days prior to screening
   and throughout the study is prohibited.

   5. If a patient is currently receiving denosumab, this must be discontinued prior to
   enrollment. Substitution with biphosphonates are acceptable.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers

This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444 as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Corvus Pharmaceuticals, Inc.

Collaborator: Genentech, Inc.

Intervention(s):

  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444 + atezolizumab
  • Drug: CPI-444

Phase:

Phase 1

Eligibility


Inclusion Criteria

   1. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

   2. Documented incurable cancer with one of the following histologies: non-small cell lung
   cancer, malignant melanoma, renal cell cancer, triple negative breast cancer,
   colorectal cancer with microsatellite instability (MSI), bladder cancer, and
   metastatic castration resistant prostate cancer.

   3. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST
   1.1).

   4. At least 1 but not more than 5 prior systemic therapies for advanced/recurrent or
   progressing disease.

Exclusion Criteria

   1. History of severe hypersensitivity reaction to monoclonal antibodies.

   2. Any active autoimmune disease or a documented history of serious autoimmune disease
   within the past 5 years requiring immunosuppressive therapy.

   3. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
   pneumonitis, idiopathic pneumonitis, or clinical symptoms of active pneumonitis.

   4. The use of any investigational medication or device in the 30 days prior to screening
   and throughout the study is prohibited.

   5. If a patient is currently receiving denosumab, this must be discontinued prior to
   enrollment. Substitution with biphosphonates are acceptable.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers

This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444 as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Corvus Pharmaceuticals, Inc.

Collaborator: Genentech, Inc.

Intervention(s):

  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444 + atezolizumab
  • Drug: CPI-444

Phase:

Phase 1

Eligibility


Inclusion Criteria

   1. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

   2. Documented incurable cancer with one of the following histologies: non-small cell lung
   cancer, malignant melanoma, renal cell cancer, triple negative breast cancer,
   colorectal cancer with microsatellite instability (MSI), bladder cancer, and
   metastatic castration resistant prostate cancer.

   3. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST
   1.1).

   4. At least 1 but not more than 5 prior systemic therapies for advanced/recurrent or
   progressing disease.

Exclusion Criteria

   1. History of severe hypersensitivity reaction to monoclonal antibodies.

   2. Any active autoimmune disease or a documented history of serious autoimmune disease
   within the past 5 years requiring immunosuppressive therapy.

   3. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
   pneumonitis, idiopathic pneumonitis, or clinical symptoms of active pneumonitis.

   4. The use of any investigational medication or device in the 30 days prior to screening
   and throughout the study is prohibited.

   5. If a patient is currently receiving denosumab, this must be discontinued prior to
   enrollment. Substitution with biphosphonates are acceptable.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers

This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444 as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Corvus Pharmaceuticals, Inc.

Collaborator: Genentech, Inc.

Intervention(s):

  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444 + atezolizumab
  • Drug: CPI-444

Phase:

Phase 1

Eligibility


Inclusion Criteria

   1. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

   2. Documented incurable cancer with one of the following histologies: non-small cell lung
   cancer, malignant melanoma, renal cell cancer, triple negative breast cancer,
   colorectal cancer with microsatellite instability (MSI), bladder cancer, and
   metastatic castration resistant prostate cancer.

   3. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST
   1.1).

   4. At least 1 but not more than 5 prior systemic therapies for advanced/recurrent or
   progressing disease.

Exclusion Criteria

   1. History of severe hypersensitivity reaction to monoclonal antibodies.

   2. Any active autoimmune disease or a documented history of serious autoimmune disease
   within the past 5 years requiring immunosuppressive therapy.

   3. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
   pneumonitis, idiopathic pneumonitis, or clinical symptoms of active pneumonitis.

   4. The use of any investigational medication or device in the 30 days prior to screening
   and throughout the study is prohibited.

   5. If a patient is currently receiving denosumab, this must be discontinued prior to
   enrollment. Substitution with biphosphonates are acceptable.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers

This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444 as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Corvus Pharmaceuticals, Inc.

Collaborator: Genentech, Inc.

Intervention(s):

  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444 + atezolizumab
  • Drug: CPI-444

Phase:

Phase 1

Eligibility


Inclusion Criteria

   1. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

   2. Documented incurable cancer with one of the following histologies: non-small cell lung
   cancer, malignant melanoma, renal cell cancer, triple negative breast cancer,
   colorectal cancer with microsatellite instability (MSI), bladder cancer, and
   metastatic castration resistant prostate cancer.

   3. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST
   1.1).

   4. At least 1 but not more than 5 prior systemic therapies for advanced/recurrent or
   progressing disease.

Exclusion Criteria

   1. History of severe hypersensitivity reaction to monoclonal antibodies.

   2. Any active autoimmune disease or a documented history of serious autoimmune disease
   within the past 5 years requiring immunosuppressive therapy.

   3. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
   pneumonitis, idiopathic pneumonitis, or clinical symptoms of active pneumonitis.

   4. The use of any investigational medication or device in the 30 days prior to screening
   and throughout the study is prohibited.

   5. If a patient is currently receiving denosumab, this must be discontinued prior to
   enrollment. Substitution with biphosphonates are acceptable.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers

This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444 as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Corvus Pharmaceuticals, Inc.

Collaborator: Genentech, Inc.

Intervention(s):

  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444 + atezolizumab
  • Drug: CPI-444

Phase:

Phase 1

Eligibility


Inclusion Criteria

   1. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

   2. Documented incurable cancer with one of the following histologies: non-small cell lung
   cancer, malignant melanoma, renal cell cancer, triple negative breast cancer,
   colorectal cancer with microsatellite instability (MSI), bladder cancer, and
   metastatic castration resistant prostate cancer.

   3. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST
   1.1).

   4. At least 1 but not more than 5 prior systemic therapies for advanced/recurrent or
   progressing disease.

Exclusion Criteria

   1. History of severe hypersensitivity reaction to monoclonal antibodies.

   2. Any active autoimmune disease or a documented history of serious autoimmune disease
   within the past 5 years requiring immunosuppressive therapy.

   3. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
   pneumonitis, idiopathic pneumonitis, or clinical symptoms of active pneumonitis.

   4. The use of any investigational medication or device in the 30 days prior to screening
   and throughout the study is prohibited.

   5. If a patient is currently receiving denosumab, this must be discontinued prior to
   enrollment. Substitution with biphosphonates are acceptable.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers

This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444 as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Corvus Pharmaceuticals, Inc.

Collaborator: Genentech, Inc.

Intervention(s):

  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444 + atezolizumab
  • Drug: CPI-444

Phase:

Phase 1

Eligibility


Inclusion Criteria

   1. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

   2. Documented incurable cancer with one of the following histologies: non-small cell lung
   cancer, malignant melanoma, renal cell cancer, triple negative breast cancer,
   colorectal cancer with microsatellite instability (MSI), bladder cancer, and
   metastatic castration resistant prostate cancer.

   3. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST
   1.1).

   4. At least 1 but not more than 5 prior systemic therapies for advanced/recurrent or
   progressing disease.

Exclusion Criteria

   1. History of severe hypersensitivity reaction to monoclonal antibodies.

   2. Any active autoimmune disease or a documented history of serious autoimmune disease
   within the past 5 years requiring immunosuppressive therapy.

   3. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
   pneumonitis, idiopathic pneumonitis, or clinical symptoms of active pneumonitis.

   4. The use of any investigational medication or device in the 30 days prior to screening
   and throughout the study is prohibited.

   5. If a patient is currently receiving denosumab, this must be discontinued prior to
   enrollment. Substitution with biphosphonates are acceptable.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers

This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444 as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Corvus Pharmaceuticals, Inc.

Collaborator: Genentech, Inc.

Intervention(s):

  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444 + atezolizumab
  • Drug: CPI-444

Phase:

Phase 1

Eligibility


Inclusion Criteria

   1. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

   2. Documented incurable cancer with one of the following histologies: non-small cell lung
   cancer, malignant melanoma, renal cell cancer, triple negative breast cancer,
   colorectal cancer with microsatellite instability (MSI), bladder cancer, and
   metastatic castration resistant prostate cancer.

   3. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST
   1.1).

   4. At least 1 but not more than 5 prior systemic therapies for advanced/recurrent or
   progressing disease.

Exclusion Criteria

   1. History of severe hypersensitivity reaction to monoclonal antibodies.

   2. Any active autoimmune disease or a documented history of serious autoimmune disease
   within the past 5 years requiring immunosuppressive therapy.

   3. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
   pneumonitis, idiopathic pneumonitis, or clinical symptoms of active pneumonitis.

   4. The use of any investigational medication or device in the 30 days prior to screening
   and throughout the study is prohibited.

   5. If a patient is currently receiving denosumab, this must be discontinued prior to
   enrollment. Substitution with biphosphonates are acceptable.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers

This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444 as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Corvus Pharmaceuticals, Inc.

Collaborator: Genentech, Inc.

Intervention(s):

  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444 + atezolizumab
  • Drug: CPI-444

Phase:

Phase 1

Eligibility


Inclusion Criteria

   1. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

   2. Documented incurable cancer with one of the following histologies: non-small cell lung
   cancer, malignant melanoma, renal cell cancer, triple negative breast cancer,
   colorectal cancer with microsatellite instability (MSI), bladder cancer, and
   metastatic castration resistant prostate cancer.

   3. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST
   1.1).

   4. At least 1 but not more than 5 prior systemic therapies for advanced/recurrent or
   progressing disease.

Exclusion Criteria

   1. History of severe hypersensitivity reaction to monoclonal antibodies.

   2. Any active autoimmune disease or a documented history of serious autoimmune disease
   within the past 5 years requiring immunosuppressive therapy.

   3. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
   pneumonitis, idiopathic pneumonitis, or clinical symptoms of active pneumonitis.

   4. The use of any investigational medication or device in the 30 days prior to screening
   and throughout the study is prohibited.

   5. If a patient is currently receiving denosumab, this must be discontinued prior to
   enrollment. Substitution with biphosphonates are acceptable.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers

This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444 as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Corvus Pharmaceuticals, Inc.

Collaborator: Genentech, Inc.

Intervention(s):

  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444 + atezolizumab
  • Drug: CPI-444

Phase:

Phase 1

Eligibility


Inclusion Criteria

   1. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

   2. Documented incurable cancer with one of the following histologies: non-small cell lung
   cancer, malignant melanoma, renal cell cancer, triple negative breast cancer,
   colorectal cancer with microsatellite instability (MSI), bladder cancer, and
   metastatic castration resistant prostate cancer.

   3. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST
   1.1).

   4. At least 1 but not more than 5 prior systemic therapies for advanced/recurrent or
   progressing disease.

Exclusion Criteria

   1. History of severe hypersensitivity reaction to monoclonal antibodies.

   2. Any active autoimmune disease or a documented history of serious autoimmune disease
   within the past 5 years requiring immunosuppressive therapy.

   3. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
   pneumonitis, idiopathic pneumonitis, or clinical symptoms of active pneumonitis.

   4. The use of any investigational medication or device in the 30 days prior to screening
   and throughout the study is prohibited.

   5. If a patient is currently receiving denosumab, this must be discontinued prior to
   enrollment. Substitution with biphosphonates are acceptable.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers

This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444 as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Corvus Pharmaceuticals, Inc.

Collaborator: Genentech, Inc.

Intervention(s):

  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444 + atezolizumab
  • Drug: CPI-444

Phase:

Phase 1

Eligibility


Inclusion Criteria

   1. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

   2. Documented incurable cancer with one of the following histologies: non-small cell lung
   cancer, malignant melanoma, renal cell cancer, triple negative breast cancer,
   colorectal cancer with microsatellite instability (MSI), bladder cancer, and
   metastatic castration resistant prostate cancer.

   3. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST
   1.1).

   4. At least 1 but not more than 5 prior systemic therapies for advanced/recurrent or
   progressing disease.

Exclusion Criteria

   1. History of severe hypersensitivity reaction to monoclonal antibodies.

   2. Any active autoimmune disease or a documented history of serious autoimmune disease
   within the past 5 years requiring immunosuppressive therapy.

   3. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
   pneumonitis, idiopathic pneumonitis, or clinical symptoms of active pneumonitis.

   4. The use of any investigational medication or device in the 30 days prior to screening
   and throughout the study is prohibited.

   5. If a patient is currently receiving denosumab, this must be discontinued prior to
   enrollment. Substitution with biphosphonates are acceptable.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers

This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444 as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Corvus Pharmaceuticals, Inc.

Collaborator: Genentech, Inc.

Intervention(s):

  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444 + atezolizumab
  • Drug: CPI-444

Phase:

Phase 1

Eligibility


Inclusion Criteria

   1. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

   2. Documented incurable cancer with one of the following histologies: non-small cell lung
   cancer, malignant melanoma, renal cell cancer, triple negative breast cancer,
   colorectal cancer with microsatellite instability (MSI), bladder cancer, and
   metastatic castration resistant prostate cancer.

   3. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST
   1.1).

   4. At least 1 but not more than 5 prior systemic therapies for advanced/recurrent or
   progressing disease.

Exclusion Criteria

   1. History of severe hypersensitivity reaction to monoclonal antibodies.

   2. Any active autoimmune disease or a documented history of serious autoimmune disease
   within the past 5 years requiring immunosuppressive therapy.

   3. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
   pneumonitis, idiopathic pneumonitis, or clinical symptoms of active pneumonitis.

   4. The use of any investigational medication or device in the 30 days prior to screening
   and throughout the study is prohibited.

   5. If a patient is currently receiving denosumab, this must be discontinued prior to
   enrollment. Substitution with biphosphonates are acceptable.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All